1. Why Allergan's Shareholders Should Be Wary About Valeant's (and Ackman's) Takeover Bid

    Why Allergan's Shareholders Should Be Wary About Valeant's (and Ackman's) Takeover Bid

    This article is by Mark Rogers, the founder and chief executive of BoardProspects.com. 

    The battle between activist investor Bill Ackman and Allergan’s chief executive and board over Valeant Pharmaceuticals’ bid to take over Allergan, the maker of Botox, has been generating a lot of news lately. But it’s what doesn’t get much press—what happens in the aftermath of such a conflict—that could have troubling consequences for shareholders down the road...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Sponsored Content
  2. Topics Mentioned

  3. Authors